New Study on Global Intravenous (IV) Iron Drugs Market Research Report 2016 | Galenica group, AMAG Pharmaceuticals, Allergan plc.

Researchmoz added Most up-to-date research on "Global Intravenous (IV) Iron Drugs Market Report: 2016 Edition" to its huge collection of research reports.

Iron is vital for multiple bodily functions, most importantly for the production of hemoglobin for red blood cells which are responsible for transporting oxygen in the blood. As an element, the only source of iron is from the diet. There is no way the body can produce iron itself. Intravenous (IV) treatment, in a broad sense, covers all the types of medications delivered intravenously, i.e. directly into the vein, through intravenous drip. Compared to the other routes of infusing medications, the intravenous route is the fastest way to deliver fluids and medications throughout the body. The first iron product for intravenous use was high-molecular-weight iron dextran. Some of the major areas of IV iron application include gynecology, gastroenterology, oncology and surgeries. Hemoglobin, Ferritin, Transferrin, and Hepcidin are major molecules which are critical in the function and regulation of iron.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=731843

The key factors driving growth of the global I.V. iron industry include increase in number of dialysis cases, increasing global healthcare expenditures, rising ageing population, increasing life expectancy rate, growing number of ERSD patients and rising medicines expenditures. Some of the noteworthy trends and developments of this industry are new product development, introduction of the first generation drugs InFed (iron dextran) and Dexeferrum (iron dextra) and feraccru treatment penetration. However, the growth of this sector is being hindered by emerging anemia management therapies and associated risks.

The report analyzes the global iron products industry along with an extensive coverage of global, Europe and the US I.V. iron market. The global IV iron market witnesses intense competition with numerous top notch players; such as Galenica Pharmaceuticals, Actavis Inc, AMAG Pharmaceuticals; operating in the marketplace along with small budding players. As a part of analysis of fierce competition prevailing in the industry, product contention has been presented in the report. The company profiles of leading aforementioned players in the market are also incorporated in the report.

By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.

Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/global-intravenous-iv-iron-drugs-market-report-2016-edition-report.html/toc

Table of Content

1. Iron in Human Body: An Introduction1.1 I.V. Iron Application Areas   
1.1.1 I.V. Iron Application in Nephrology
1.2 Iron Deficiency - Anemia   
1.2.1 Iron Deficiency Metrics   
1.3 I.V. Iron Therapies for Anemia Treatment   
1.4 Types of I.V. Iron

2. Global Iron Product Market Analysis
2.1 Global Iron Product Market by Value   
2.2 Global Iron Products Market Share by Segment

3. Global I.V. Iron Drugs Market Analysis
3.1 Global I.V. Iron Drugs Market by Value   
3.2 Global I.V. Iron Drugs Market by Product   
3.3 Global I.V. Iron Drugs Market Share by Product

4. I.V. Iron Drugs Regional Market Analysis
4.1 European I.V. Iron Drug Market   
4.1.1 European I.V. Iron Drug Market by Value   
4.1.2 European I.V. Iron Drug Market by Product   
4.1.3 European I.V. Iron Drug Market Share by Product
4.2 The US I.V. Iron Drug Market   
4.2.1 The US I.V. Iron Drug Market by Value   
4.2.2 The US I.V. Iron Drug Market by Product   
4.2.3 The US I.V. Iron Drug Market Share by Product   
4.2.4 The US Non-dialysis I.V. Iron Drug Market by Volume   
4.2.5 The US Non-dialysis I.V. Iron Drug Market Share by Product

5. Market Dynamics
5.1 Growth Drivers
5.1.1 Increase in Number of Dialysis Cases   
5.1.2 Increasing Healthcare Expenditure   
5.1.3 Increasing Cases of CKD and ESRD   
5.1.4 Rising Ageing Population   
5.1.5 Shift from Rural to Urban Regions   
5.1.6 Prevalence of Iron Deficiency in Women   
5.1.7 Increasing Life Expectancy Rate   
5.1.8 Rising Medicines Expenditures   
5.1.9 Growing Number of ERSD Patients
5.2 Trends
5.2.1 New Product Development   
5.2.2 Introduction of First Generation Drugs InFeD and Dexeferrum   
5.2.3 Feraccru Treatment Penetration
5.3 Challenges
5.3.1 Emerging Anemia Management Therapies
5.3.2 Potential Risks of I.V. Iron

6. Competitive Landscape
6.1 Product Comparison

Continue...

Make an Enquiry of this report @ https://www.researchmoz.us/enquiry.php?type=E&repid=731843

New Study Reveals Global Intravenous (I.V.) Iron Drugs Market Analysis and Outlook 2015

Researchmoz added Most up-to-date research on "Global Intravenous (I.V.) Iron Drugs Market Report: 2015 Edition" to its huge collection of research reports.

Iron deficiency anemia is the most common form of anemia throughout the world. It is estimated that two billion people suffer from iron deficiency anemia worldwide. To address iron deficiency, iron therapy is important being the critical factor in the production of red blood cells. Around 4.5 million Americans are diagnosed and suffering from iron deficiency anemia (IDA).

Generally, daily oral iron is the first line therapy for most IDA patient but for many patients oral iron therapy fails as a consequence of compliance, efficacy and side effects like constipation and gastro intestinal disorders. When oral supplements fail to meet the requirement, intravenous (I.V.) iron therapy is used, in which iron is directly injected with a needle into a vein. Iron given intravenously allows larger amounts of iron to be provided to patients while avoiding many of the side effects and treatment compliance issues associated with oral iron, and can result in faster rises in hemoglobin levels. In the US, a small fraction of non-dialysis CKD patients who are diagnosed with IDA are currently being treated with I.V. iron, and thus a significant opportunity is there for the market.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=285761

The key factors driving growth of the global I.V. iron industry include iron deficiency in hemodialysis patient cases, growing number of ERSD patients, prevalence of iron deficiency in women, increasing global healthcare expenditure, increasing global ageing population and large potential in new therapeutic areas. Some of the noteworthy trends and developments of this industry are penetration of I.V. iron in obstetrics and gynecology area, new product development and increase in awareness of disease. However, the growth of this sector is hindered by potential risks of using I.V. iron, emerging anemia management therapies and strict regulatory structures.

The report provides a comprehensive study of iron product market and I.V. iron market globally. It also provides detailed information for key regional markets of I.V iron industry. The competition in the global I.V. iron market is stiff among large players like Galenica Group, AMAG Pharmaceuticals Inc. and Actavis Plc. All these companies have been profiled in the present report highlighting their key financials and business strategies for growth.

By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.

Table of Content

1. Overview1.1 I.V. Iron Application Areas
1.1.1 I.V. Iron Application in Nephrology
1.2 Iron Deficiency - Anemia
1.2.2 Iron Deficiency Metrics
1.3 I.V. Iron Therapies for Anemia Treatment

2. Market Analysis
2.1 Global Iron Product Market

- Market Value
- Market Segments

2.2.1 Global I.V. Iron Drug Market

- Market Value
- Product Share

2.2 Regional Analysis
2.2.1 The US I.V. Iron Drug Market

- Market Value
- Product Share
- Non-Dialysis IV Iron Market

2.2.2 European I.V. Iron Drug Market

- Market Value
- Product Share

2.2.3 Australian I.V. iron Drug Market

- Market Value
- Product Share

3. Market Dynamics
3.1 Growth Drivers
3.1.1 Iron Deficiency in Hemodialysis Patients Cases
3.1.2 Growing Number of ERSD Patients
3.1.3 Prevalence of Iron Deficiency in Women
3.1.4 Increasing Global Healthcare Expenditure
3.1.5 Increasing Global Ageing Population
3.1.6 Large Potential in New Therapeutic Areas
3.2 Key Trends
3.2.1 I.V. Iron Penetration in Obstetrics and Gynecology Area
3.2.2 New Product Development
3.2.3 Increase Disease Awareness
3.3 Challenges
3.3.1 Potential Risks of I.V. Iron
3.3.2 Emerging Anemia Management Therapies
3.3.3 Strict Regulatory Structures

4. Competitive Landscape
4.1 Global Market
4.2 Regional Market
4.2.1 The US
4.2.2 Europe
4.3 Product Comparison

5. Company Profiles
5.1 Galenica group
5.1.1 Business Overview
5.1.2 Financial Overview
5.1.3 Business Strategies

- Executing an Iron Deficiency Franchise
- Exploit the Commercial Potential

5.2 AMAG Pharmaceuticals
5.2.1 Business Overview
5.2.2 Financial Overview
5.2.3 Business Strategies

- Capture a Larger Market Share
- Feraheme in Non-Dialysis Adult CKD Patients

5.3 Actavis Plc
5.3.1 Business Overview
5.3.2 Financial Overview
5.3.3 Business Strategies

- Development through Mergers & Acquisitions
- Differentiated and High-Demand Products

6. Market Outlook
6.1 Market Forecast
6.2 Forecast Methodology
6.2.1 Dependent and Independent Variables
6.2.2 Correlation Analysis
6.2.3 Regression Analysis 

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=285761

New Study Reveals Global Intravenous (IV) Iron Drugs Market Analysis & Outlook (2017-2021)

Researchmoz added Most up-to-date research on "Global Intravenous (IV) Iron Drugs Market: Industry Analysis & Outlook (2017-2021)" to its huge collection of research reports.

Iron is among the vital minerals present in the human body. It is one of the components of hemoglobin, the substance present in red blood cells that carries oxygen throughout the body through blood, and oxygen is further utilized by the cells to produce energy required to perform all the required functions. Therefore, decline in the body’s supply of iron can lead to severe problems. The balance of iron in the body primarily is a combined result of three dynamics- intake, losses and metabolic demand.

Intravenous (I.V.) treatment, in a broad sense, covers all the types of medications delivered intravenously, i.e. directly into the vein, through intravenous (I.V.) drip. Compared to the other routes of infusing medications, the intravenous route is the fastest way to deliver fluids and medications throughout the body. Also, this method ensures 100% bioavailability, which means that the chemicals delivered are fully absorbed by the body.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1109587

The report “Global I.V. Iron Drugs Market” provides a comprehensive study of iron product market and I.V. iron market globally. It also provides detailed information for key regional markets of I.V iron industry. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The major players in the industry, Galenica Group, AMAG Pharmaceuticals and Allergan are being profiled. All these companies have been profiled in the present report highlighting their key financials and business strategies for growth.

The key factors driving the growth of I.V. iron drugs market are growing ageing population, growing urbanization, increase in number of dialysis cases, rising healthcare expenditure and increasing life expectancy rate. Some of the noteworthy trends and developments of this industry are paradigm shift from oral iron drugs to intravenous iron drugs and introduction of first generation drugs InFeD and Dexeferrum. However, the expansion of the market is hindered by potential risks of I.V. iron.

Table of Content

1. I.V. Iron Market - An Overview1.1 Iron in Human Body: An Introduction
1.2 I.V. Iron Application Areas
1.3 I.V. Iron Applications in Nephrology
1.4 Iron Deficiency - Anemia
1.5 Iron Therapies for Anemia Treatment

2. Global Iron Product Market Analysis
2.1 Global Iron Product Market by Value
2.2 Global Iron Product Market Forecast by Value
2.3 Global Iron Product Market by Segments

3. Global I.V. Iron Drugs Market Analysis
3.1 Global I.V. Iron Drugs Market by Value
3.2 Global I.V. Iron Drugs Market Forecast by Value
3.3 Global I.V. Iron Drugs Market by Product Category
3.4 Global I.V. Iron Drugs Market Share by Product Category
3.5 Global I.V. Iron Drugs Market Share by Segments

4. Regional Market Analysis
4.1 The US
4.1.1 The US I.V. Iron Drug Market by Value
4.1.2 The US I.V. Iron Drug Market Forecast by Value
4.1.2 The US I.V. Iron Drug Market by Product Category
4.1.3 The US I.V. Iron Drug Market Share by Product Category
4.1.4 The US Non-dialysis I.V. Iron Drug Market by Volume
4.1.5 The US Non-dialysis I.V. Iron Drug Market Forecast by Volume
4.1.6 The US Non-dialysis I.V. Iron Drug Market Share by Product
4.2 Europe
4.2.1 European I.V. Iron Drug Market by Value
4.2.2 European I.V. Iron Drug Market Forecast by Value
4.2.3 European I.V. Iron Drug Market by Product Category
4.2.4 European I.V. Iron Drug Market Share by Product Category

5. Market Dynamics
5.1 Growth Drivers
5.1.1 Growing Ageing Population
5.1.2 Growing Urbanization
5.1.3 Increase in Number of Dialysis Cases
5.1.4 Rising Healthcare Expenditure
5.1.5 Increasing Life Expectancy Rate
5.2 Market Trends
5.2.1 Paradigm Shift from Oral Iron Drugs to Intravenous Iron Drugs
5.2.2 Introduction of First Generation Drugs InFeD and Dexeferrum
5.3 Challenges
5.3.1 Potential Risks of I.V. Iron

6. Competitive Landscape
6.1 Comparison between Injectafer, Venofer, INFeD and Feraheme

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=1109587